Sincalide

From Infogalactic: the planetary knowledge core
Jump to: navigation, search

Lua error in package.lua at line 80: module 'strict' not found.

Sincalide
File:Sincalide.svg
Systematic (IUPAC) name
α-aspartyl-O-sulfotyrosylmethionylglycyltryptophylmethionyl-α-aspartylphenylalaninamide
Clinical data
AHFS/Drugs.com Micromedex Detailed Consumer Information
Pregnancy
category
  • US: B (No risk in non-human studies)
Legal status
  • US: ℞-only
  • Available on a named-patient basis (UK)
Routes of
administration
Intravenous
Identifiers
CAS Number 25126-32-3 YesY
ATC code V04CC03 (WHO)
PubChem CID: 32800
IUPHAR/BPS 864
ChemSpider 8009168 N
UNII M03GIQ7Z6P N
KEGG D05845 YesY
ChEMBL CHEMBL1121 N
Synonyms 1-De(5-oxo-L-proline)-2-de-L-glutamine-
5-L-methioninecaerulein, 3-[[2-[[2-[[2-[[2-[[2-[(2-amino-3-carboxy-propanoyl)
amino]-3-(4-sulfooxyphenyl)propanoyl]amino]-4-
methylsulfanyl-butanoyl]amino]acetyl]amino]-3-
(1H-indol-3-yl)propanoyl]amino]-4-methylsulfanyl-
butanoyl]amino]-3-[(1-carbamoyl-2-phenyl-ethyl)
carbamoyl]propanoic acid
Chemical data
Formula C49H62N10O16S3
Molecular mass 1143.27 g/mol
  • CSCC[C@@H](C(=O)NCC(=O)N[C@@H](CC1=CNC2=CC=CC=C21)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H](CC3=CC=CC=C3)C(=O)N)NC(=O)[C@H](CC4=CC=C(C=C4)OS(=O)(=O)O)NC(=O)[C@H](CC(=O)O)N
  • InChI=1S/C49H62N10O16S3/c1-76-18-16-34(55-47(69)37(58-44(66)32(50)23-41(61)62)21-28-12-14-30(15-13-28)75-78(72,73)74)45(67)53-26-40(60)54-38(22-29-25-52-33-11-7-6-10-31(29)33)48(70)56-35(17-19-77-2)46(68)59-39(24-42(63)64)49(71)57-36(43(51)65)20-27-8-4-3-5-9-27/h3-15,25,32,34-39,52H,16-24,26,50H2,1-2H3,(H2,51,65)(H,53,67)(H,54,60)(H,55,69)(H,56,70)(H,57,71)(H,58,66)(H,59,68)(H,61,62)(H,63,64)(H,72,73,74)/t32-,34-,35-,36-,37-,38-,39-/m0/s1 N
  • Key:IZTQOLKUZKXIRV-YRVFCXMDSA-N N
 NYesY (what is this?)  (verify)

Sincalide (INN) is a cholecystokinetic drug administered by injection to aid in diagnosing disorders of the gallbladder and pancreas. It is the 8-amino acid C-terminal fragment of cholecystokinin, and also known as CCK-8.

Common adverse effects following administration include abdominal discomfort and nausea. These effects are more pronounced following rapid infusion.

Clinical Use

Indications

Sincalide may be used to stimulate gallbladder contraction, as may be assessed by contrast agent cholecystography or ultrasonography, or to obtain by duodenal aspiration a sample of concentrated bile for analysis of cholesterol, bile salts, phospholipids, and crystals. It can also be used to stimulate pancreatic secretion (especially in conjunction with secretin) prior to obtaining a duodenal aspirate for analysis of enzyme activity, composition, and cytology. In some instances it is used to accelerate the transit of a barium meal through the small bowel, thereby decreasing the time and-extent of radiation associated with fluoroscopy and x-ray examination of the intestinal tract.[1]

External links

References

  1. Kinevac Package Insert


<templatestyles src="Asbox/styles.css"></templatestyles>